Neumora Q3 net loss $53.0M; cash $519.5M; navacaprant Phase 3 on track

Neumora Therapeutics, Inc.

2023-Q3 EPS reported -$3.59

Net loss of $53.0M in Q3 2023 vs. $29.3M in Q3 2022, driven by higher R&D costs ($41.6M vs. $22.5M).
Cash, cash equivalents and marketable securities of $519.5M as of Sept 30, 2023; expected to fund operations into 2026.
Navacaprant (KOR antagonist) Phase 3 KOASTAL trials ongoing; KOASTAL-1 topline data expected H2 2024; bipolar depression trial planned H1 2024.
Completed IPO in Sept 2023; shares began trading on Nasdaq under NMRA; raised over $850M since inception.
Appointed Robert Lenz, M.D., Ph.D., as EVP, head of R&D in October 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Neumora Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $53.0 million.

Period: the third quarter ended September 30, 2023
Net income: $53.0 million
Result: reported results

Exact text from the filing

The Company reported a net loss of $53.0 million for the third quarter of 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Neumora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-268165

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.